Upstream_Logo_CMYK.png
Upstream Bio Announces Oral Presentation of New Data from a Phase 1b Multiple Ascending Dose Trial of Verekitug (UPB-101) in Adults with Asthma at the European Respiratory Society Congress
September 09, 2024 08:00 ET | Upstream Bio, Inc.
Upstream gives oral presentation of clinical data for verekitug in patients with severe asthma at European Respiratory Society congress
Atyr_Logo.png
aTyr Pharma Announces Second Quarter 2023 Results and Provides Corporate Update
August 09, 2023 16:00 ET | aTyr Pharma, Inc.
Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis currently enrolling in the U.S., Europe and Japan. Phase 2 EFZO-CONNECT™ study of efzofitimod in SSc-ILD expected to initiate in the...
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen to Report Fourth Quarter and Full Year 2022 Financial Results
February 17, 2023 07:00 ET | FibroGen, Inc.
SAN FRANCISCO, Feb. 17, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its fourth quarter and full year 2022 financial results on Monday, February 27 after the market close....
Atyr_Logo.png
aTyr Pharma Announces Two Abstracts for ATYR1923 Accepted for Presentation at the European Respiratory Society International Congress
August 09, 2021 08:00 ET | aTyr Pharma, Inc.
SAN DIEGO, Aug. 09, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
ssek-llp logo 2.JPG
Shepherd, Smith, Edwards & Kantas Assisting Puerto Rico ERS Bondholders Collect $3 Billion in Previously Invalidated Collateral
March 20, 2019 09:17 ET | Shepherd Smith Edwards & Kantas LLP
HOUSTON, March 20, 2019 (GLOBE NEWSWIRE) -- Lawyers with the firm Shepherd, Smith, Edwards & Kantas, LLP (SSEK Law Firm) are assisting Employee Retirement System (ERS) bondholders gain access to...
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen Announces Pamrevlumab Oral and Poster Presentations at European Respiratory Society International Congress 2017
September 05, 2017 16:05 ET | FibroGen, Inc.
SAN FRANCISCO, Sept. 05, 2017 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, today announced oral and poster presentations on pamrevlumab, an anti-CTGF...